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Objectives
Natural humoral immune response and autoimmune
mechanisms have great importance in keeping the
balance of tumorimmunity, although it has not yet been
fully understood. We aimed to reveal potential anti-
tumor immune response by immunoglobulin (Ig) profile
analysis of patients with metastatic melanomas.
Methods
A complex panel assay has been performed at expressed
DNA and protein levels on antibodies originating from
patients’ peripheral blood (n = 92) or cancerous tissue
biopsies (n= 87) (ETT TUKEB 16462- 02/2010). Heavy
and light chain immunoglobulin variable gene regions
were sequenced and analysed with Vector NTI Advance
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Figure 1 Human purified immunoglobulin of patient (a/) and antibody fragments developed (b/) show cancer associated antigen specific
binding on SK-Mel 28 cells and melanoma tissues.
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11, Bioedit 7.0, ClustalX2.0.11, TreeView 1.6.6 programs
using available databases (IMGT, Blast). Patients’ sera,
purified human Ig preparations and antibody fragments
from tumor infiltrating B cells were tested by ELISA,
immunofluorescence FACS and confocal laser microscopy.
Results
Cluster analysis revealed specific antibody variable
region gene subgroups in the VH3 family, amongst
which there are the ones with cancer associated antigen
binding capacity. The purified immunoglobulin’s strong
SK-Mel28 melanoma binding potential paralleled with
the clinical outcome. Some selected expressed antibody
fragments showed tumor associated antigen labelling on
melanoma tissues (Fig. 1). A competitive cell membrane
ELISA has been standardized for measuring patients’
sera in terms of various cancer associated antigen bind-
ing capacity. Data are under evaluation concerning their
value to predict anti cancer humoral immune response.
Conclusions
We could prove the extensive presence of highly tumor
associated unique GD3 sialilated glycosphingolipid spe-
cific antibody variable regions in patients with mela-
noma. Our novel panel assay confirmed the potentials
of antibody profile analysis in characterizing anti tumor
humoral immune response and its worth for diagnostics.
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